BPI-9016M
Emibetuzumab
Rilotumumab
Onartuzumab
Ficlatuzumab
Narnatumab
(rel)-Tivantinib
Davutamig
c-Met-IN-18
Tepotinib
Dihexa
c-Met-IN-2
Ensartinib
c-Met-IN-1
Meleagrin
PF-04217903 phenolsulfonate
MET kinase-IN-2
Norleual
c-Met-IN-9
c-Met/HDAC-IN-2